Merck accelerates cancer immunotherapy program with collaborations

|About: Merck & Co Inc. (MRK)|By:, SA News Editor

Merck (MRK) says it has entered three separate collaboration agreements with Pfizer (PFE), Amgen (AMGN) and Incyte (INCY) to evaluate MRK's investigational MK-3475 immunotherapy cancer treatment, part of a new class of experimental drugs that unleash the body's immune system to target cancer cells.

MRK will collaborate on studies of MK-3475 in combination with therapies from the other drugmakers; financial terms weren't provided about the collaborations.

R&D chief Roger Perlmutter says MRK is looking at MK-3475 across a wide range of cancers, both as a standalone therapy and in combination with other treatments.

Earlier: MRK net profits falls 14%.